Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study

Detalles Bibliográficos
Autores principales: Zang, Zhijiang, Wang, Ziting, Chiong, Edmund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Editorial Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324806/
https://www.ncbi.nlm.nih.gov/pubmed/35384091
http://dx.doi.org/10.1111/iju.14891
_version_ 1784756889342443520
author Zang, Zhijiang
Wang, Ziting
Chiong, Edmund
author_facet Zang, Zhijiang
Wang, Ziting
Chiong, Edmund
author_sort Zang, Zhijiang
collection PubMed
description
format Online
Article
Text
id pubmed-9324806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93248062022-07-30 Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study Zang, Zhijiang Wang, Ziting Chiong, Edmund Int J Urol Editorial Comment John Wiley and Sons Inc. 2022-04-05 2022-06 /pmc/articles/PMC9324806/ /pubmed/35384091 http://dx.doi.org/10.1111/iju.14891 Text en © 2022 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Editorial Comment
Zang, Zhijiang
Wang, Ziting
Chiong, Edmund
Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
title Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
title_full Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
title_fullStr Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
title_full_unstemmed Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
title_short Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
title_sort editorial comment to safety and efficacy of apalutamide in japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: final report for the japanese subpopulation analysis of the randomized, placebo‐controlled, phase iii titan study
topic Editorial Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324806/
https://www.ncbi.nlm.nih.gov/pubmed/35384091
http://dx.doi.org/10.1111/iju.14891
work_keys_str_mv AT zangzhijiang editorialcommenttosafetyandefficacyofapalutamideinjapanesepatientswithmetastaticcastrationsensitiveprostatecancerreceivingandrogendeprivationtherapyfinalreportforthejapanesesubpopulationanalysisoftherandomizedplacebocontrolledphaseiiititanstudy
AT wangziting editorialcommenttosafetyandefficacyofapalutamideinjapanesepatientswithmetastaticcastrationsensitiveprostatecancerreceivingandrogendeprivationtherapyfinalreportforthejapanesesubpopulationanalysisoftherandomizedplacebocontrolledphaseiiititanstudy
AT chiongedmund editorialcommenttosafetyandefficacyofapalutamideinjapanesepatientswithmetastaticcastrationsensitiveprostatecancerreceivingandrogendeprivationtherapyfinalreportforthejapanesesubpopulationanalysisoftherandomizedplacebocontrolledphaseiiititanstudy

Ejemplares similares